KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Other (2016)

Historic Receivables - Other for Biomarin Pharmaceutical (BMRN) over the last 5 years, with Q3 2016 value amounting to $8.4 million.

  • Biomarin Pharmaceutical's Receivables - Other changed N/A to $8.4 million in Q3 2016 from the same period last year, while for Sep 2016 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $116.5 million for FY2013, which is N/A changed from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Receivables - Other of $8.4 million as of Q3 2016.
  • In the past 5 years, Biomarin Pharmaceutical's Receivables - Other ranged from a high of $116.5 million in Q4 2013 and a low of $6.8 million during Q1 2012
  • Moreover, its 3-year median value for Receivables - Other was $9.0 million (2012), whereas its average is $30.1 million.
  • Examining YoY changes over the last 5 years, Biomarin Pharmaceutical's Receivables - Other showed a top increase of 11189.86% in 2012 and a maximum decrease of 2380.56% in 2012.
  • Biomarin Pharmaceutical's Receivables - Other (Quarter) stood at $9.0 million in 2012, then soared by 1191.86% to $116.5 million in 2013, then crashed by 92.79% to $8.4 million in 2016.
  • Its Receivables - Other was $8.4 million in Q3 2016, compared to $116.5 million in Q4 2013 and $9.0 million in Q3 2012.